Tian B, Deng Y, Cai Y, et al. - Through searching PubMed, EMBASE, Web of Science and Cochrane Library from their inception to May 2020, researchers sought to assess the efficacy and safety of combination therapy in patients with T2DM with SGLT2 inhibitors and RAS blockers, such as ACEI/ARB. Seven studies including 1757 patients have been analyzed. The combination therapy with SGLT2 inhibitors and ACEI/ARB in T2DM was effective and well-tolerated compared with ACEI/ARB alone and was able to achieve additional effects, including better blood pressure control, improved renal outcomes, alleviation of long-term renal function, and decreased blood glucose and body weight. An increased risk of hypoglycemia was demonstrated by combination therapy.